Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05583149 · ClinicalTrials.gov registry record · Phase 2

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

A Phase 2 study of Refractory B-Cell Non-Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Patrick C. Johnson, MD.

Active
Registry status
Phase 2
Development phase
28
Enrollment target
2
Study locations

NCT05583149 is a Phase 2 study of Refractory B-Cell Non-Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma (DLBCL) that is active but no longer recruiting, run by Patrick C. Johnson, MD. The registered enrollment target is 28 participants, below the 46-participant average among 15 other Refractory B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (39% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05583149, a Phase 2 study of Refractory B-Cell Non-Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma (DLBCL), is active but no longer recruiting, sponsored by Patrick C. Johnson, MD.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
28 participants
Enrollment target
2
Study locations

Study Summary

This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabrutinib in combination with lisocabtagene maraleuce

Conditions Studied

Refractory B-Cell Non-Hodgkin Lymphoma Diffuse Large B Cell Lymphoma (DLBCL) T-Cell/Histiocyte-Rich Large B-Cell Lymphoma DLBCL, Nos Genetic Subtypes EBV-Positive DLBCL, Nos Refractory Aggressive B-cell Lymphomas Aggressive B-cell NHL De Novo or Transformed Indolent B-cell Lymphoma Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL) High-Grade B-Cell Lymphoma, Nos

Interventions

  • DRUG Lymphodepleting chemotherapy
  • DRUG ACALABRUTINIB
  • DRUG LISOCABTAGENE MARALEUCEL

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Beth-Israel Deaconess Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2023-03-01
Est. Completion 2029-03-01
Phase Phase 2

Sponsor

Patrick C. Johnson, MD

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05583149

The ClinicalTrials.gov registry entry for NCT05583149 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 46-participant average among 15 other Refractory B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (39% lower). The listed sponsor is Patrick C. Johnson, MD, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Refractory B-Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Lymphodepleting chemotherapy is the first listed.

NCT05583149 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05583149 about?

NCT05583149 is a clinical study titled "Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas". This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabrutinib in combination with lisocabtagene maraleuce

What is the current status of trial NCT05583149?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2023-03-01. Estimated completion is 2029-03-01.

What conditions does trial NCT05583149 study?

This clinical trial studies the following conditions: Refractory B-Cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, DLBCL, Nos Genetic Subtypes, EBV-Positive DLBCL, Nos.

What interventions are being tested in trial NCT05583149?

The interventions under investigation include: Lymphodepleting chemotherapy (DRUG), ACALABRUTINIB (DRUG), LISOCABTAGENE MARALEUCEL (DRUG).

Who is sponsoring clinical trial NCT05583149?

This trial is sponsored by Patrick C. Johnson, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05583149 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory B-Cell Non-Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Refractory B-Cell Non-Hodgkin Lymphoma

All registered trials for this condition

Diffuse Large B Cell Lymphoma (DLBCL)

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.